Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Globalisation increases risk of emerging disease spread
Globalisation increases the risk of emeging disease spread
Gareth Hateley said that Schmallenberg virus (SBV) is no longer a notifiable disease.
The final morning of the BCVA Congress at Hinkley saw updates on two recently emerged diseases

Lottie Bell, from the Roslin Institute, reminded delegates that 'bleeding calf syndrome' or bovine neonatal pancytopenia (BNP) was first reported in the UK in 2009 having emerged in continental Europe in 2007.

She explained that a strong epidemiological association between BNP and administration of a particular inactivated bovine viral diarrhoea vaccine (Pregsure) to the dams of affected calves has been reported. Studies suggest that BNP is mediated by the transfer of alloantibodies in colostrum, and these alloantibodies recognise major histocompatibility complex (MHC) class I molecules – the major tissue-type antigens that mediate graft rejection.

The ingestion of these alloantibodies by newborn calves via the colostrum causes rapid destruction of peripheral blood and bone marrow cells, resulting in the dramatic haemorrhagic signs seen in clinical cases. Colostrum from BNP-affected cows will induce the condition in unaffected calves and there is also a subclinical form of BNP in 15% of clinically normal calves.

The speaker suggested that it is important to handle BNP-affected calves gently in order to avoid exacerbating haemorrhage; long acting antibiotic therapy is a sensible precautionary measure; but that blood transfusion can be beneficial provided that administration is carried out with great care.

In addition, pooling of colostrum on affected farms should be avoided and consideration should be given to breeding from a different bull. The only certain solution is to cull cows that are known to have given birth to BNP-affected calves.

The second speaker, Gareth Hateley, from the APHA VI Centre in Thirsk, said that Schmallenberg virus (SBV) is no longer a notifiable disease and that this may lead to a degree of under-reporting, with the consequent risk that farmers and their advisers might underestimate the risk of re-infection in enzootic areas.

He reminded delegates of the congenital malformations seen in SBV-affected calves, of its spread via different Culicoides midges and that it was not zoonotic. Overwintering of the virus is possible via the vector and one bite is sufficient to transmit the disease.

Susceptible species include cattle, sheep and goats (camelids seroconvert) and infected animals show viraemia within two to five days of being bitten. The teratogenic effects develop in utero between days 60 - 150 of infection.

It is a disease of acute onset and generally low incidence in cattle – there was one outbreak in March this year in the south west of the UK – but occasionally high infectivity in sheep (up to 30% has been reported). Immunity may last for two years and vaccination is effective. Gareth told delegates that an effective vaccine had been produced rapidly by the pharmaceutical industry and "we should be mindful of the maxim 'use it or lose it'".

In conclusion, he suggested that other similar vector-borne diseases were just over the horizon, including Rift Valley Fever, West Nile Virus Fever and new strains of bluetongue virus; and that climate change and globalisation were constantly enhancing the risk.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.